Our Founder

Mir Imran.

Mir’s passion is identifying, understanding and solving poorly or unmet clinical needs, which has led to his prolific track record of building companies. Mir is motivated by his desire to positively impact the lives of millions of patients, and he has become one of the leading inventors and entrepreneurs in the field. Rani has the potential to be one of his greatest achievements yet.

Expertise.

Mir has a unique background in medicine and engineering, which became the foundation of his work in innovation and company building.  After attending medical school, Mir began his career as a healthcare entrepreneur in the late 1970’s and has founded more than 20 life sciences companies since those early days, more than half of which have been acquired. Mir is perhaps most well-known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator (ICD).

Accomplishments.

Mir is one of the most prolific inventors in healthcare, and often can be found in his lab working side by side with his engineers. Mir has had a lifetime of success in innovation creation and company building.  Mir has received numerous industry accolades for his track record of success in developing and commercializing breakthrough medical innovations.

  • Top 50 Medical Device Inventors Of All Time
  • National Academy of Inventors
  • National Academy of Engineers
  • PharmaVoice 100

“Millions must take injections to slow the progression of their condition.  With pills, compliance is much higher than with injections which helps slow down chronic diseases.”

Mir Imran, Founder and Executive Chairman

“I am passionate about changing healthcare and coming up with new solutions that will impact the lives of millions of patients.”

Mir Imran, Founder and Executive Chairman

“Given the market demand and potential, it’s no wonder that there have been countless attempts and dollars spent by companies to try to convert painful injections into painless pills.”

Mir Imran, Founder and Executive Chairman

MEDIA

Rani Therapeutics Lead Program Achieves Endpoints In Repeat-Dose Part Of Osteoporosis Study

Read Article

MEDIA

Rani Therapeutics reveals results from phase 1 osteoporosis study

Read Article